Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Insiders At Aurinia Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Siemens Healthineers AG (OtherSEMHF)
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Express News | Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024
Express News | Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024
Aurinia to Participate in Jefferies London Healthcare Conference
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $10.85
Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management
Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating
Aurinia Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced a Workforce Reduction.
Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript Summary
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Aurinia Pharmaceuticals: Strong Growth Prospects Bolstered by Lupkynis Sales and Promising Pipeline
Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring
Aurinia Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development